Clinical Trial Patient Selection Study: Another Success Story at Wax-it Histology​​

A client at Wax-it engaged in drug development required a detailed study of a specific, complex signaling pathway integral to their groundbreaking cancer drug. This pathway, involving fourteen distinct proteins and signaling molecules, was pivotal for understanding the drug’s mechanism of action and potential therapeutic impact. The working hypothesis was that if
patients with the correct protein expression profile are identified, the clinical trial will have a better success rate.

Wax-it Histology Services conducted an in-depth analysis of these fourteen targets, using six different antibodies per target. Through our immunohistochemistry (IHC) optimization program, we developed IHC protocols for each target protein. As a result, we identified the best antibody test panel of the specific cancer type our client was targeting.

Following a comprehensive pathology review, we identified seven key target proteins that were upregulated or downregulated in the specific type of cancer. Using this crucial information, we developed a test panel to aid in patient selection for clinical trials, significantly saving time and financial resources.

This study showcases our expertise in histopathology and our commitment to supporting groundbreaking research, ultimately contributing to more efficient and effective cancer treatments.